Liver Disease: Awareness Must Ramp

Here’s a concise summary of the article “Low awareness of Metabolic dysfunction–associated steatotic liver disease (MASLD) among U.S. adults: Trends from National Health and Nutrition Examination Survey (NHANES) 2017–2023” by Alp et al., Hepatology Communications...

VA Innovation in Liver Disease

The VA continues to innovate in healthcare generally and liver disease specifically. Including with GLP-1s–“GLP1-RA reduces risk of death in liver disease patients Researchers from VA Orlando and the University of Florida reported Veterans with...

NITs and Semaglutide

FROM THE RECENT PAPER regarding diagnostic testing and weight loss medication:”Conclusion: Non-Invasive Tests (NITs) may be used for assessing a treatment response in patients with MASH. Further studies should confirm the treatment effect of NITs and evaluate...

Novo Nordisk Buys Akero

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today...

Depression and MASLD

This October 2025 paper, titled “Association between depression and metabolic dysfunction-associated steatotic liver disease: a cross-sectional analysis from the paracelsus 10,000 Study,” has this summary–“In this large, population-based...